PTI reported Bharat Biotech chairman and managing director, Krishna Ella, as saying in a session of TiE Global Summit that two more facilities could be established for vaccine manufacturing including Covaxin, a vaccine for the coronavirus.
“I think it will enter into Phase I (next month) because it is going to be a single-dose vaccine. The clinical trial process is also going to be faster.”
In September, Bharat Biotech signed a licensing agreement with Washington University School of Medicine in St. Louis for a novel chimp adenovirus, single-dose intranasal vaccine for Covid-19.
Market Data 
Markets 
AI
